Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Daria Zhuravleva"'
Autor:
Daniil L. Stroyakovskiy, Natalya V. Fadeeva, Marina P. Matrosova, Konstantin G. Shelepen, Grigoriy A. Adamchuk, Bodhisatta Roy, Rajnish Nagarkar, Mahesh Kalloli, Daria Zhuravleva, Georgiy D. Voevodin, Mariya S. Shustova, Fedor Kryukov
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background BCD-021 is a bevacizumab biosimilar which was shown to be equivalent to reference bevacizumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clin
Externí odkaz:
https://doaj.org/article/29165df1463e460abb9610caf5d24925
Autor:
Daria Zhuravleva, 邰利雅
104
Introduction: Traveling abroad for getting medical treatment is becoming more popular recently among the governments, economists, media, and researchers. Russian people are among those attracted by medical tourism destinations. Countries, th
Introduction: Traveling abroad for getting medical treatment is becoming more popular recently among the governments, economists, media, and researchers. Russian people are among those attracted by medical tourism destinations. Countries, th
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/88579336430780601473
Autor:
Daniil Stroyakovskiy, Natalya Fadeeva, Marina Matrosova, Konstantin Shelepen, Grigoriy Adamchuk, Bodhisatta Roy, Rajnish Nagarkar, Mahesh Kalloli, Daria Zhuravleva, Georgiy Voevodin, Mariya Shustova, Fedor Kryukov
Background BCD-021 is a bevacizumab biosimilar which was shown to be equivalent to reference bevacizumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clinical tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c576b5cd120f7be5c0b189e608f80722
https://doi.org/10.21203/rs.3.rs-763106/v1
https://doi.org/10.21203/rs.3.rs-763106/v1